Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 381, Issue 26, Pages 2491-2493Publisher
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMp1913547
Keywords
-
Categories
Ask authors/readers for more resources
On October 3, the FDA approved coformulated tenofovir alafenamide and emtricitabine (F/TAF) for HIV prevention in at-risk adults and adolescents horizontal ellipsis excluding those who have receptive vaginal sex. F/TAF's story highlights numerous flaws in the drug-approval process.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
